Marc De Hert, M.D. Ph.D., Professor Psychiatry, UPC KU Leuven, Campus Kortenberg, Leuvense Steenweg 517, B-3070 Kortenberg, Belgium
|
|
- Alaina Daniels
- 8 years ago
- Views:
Transcription
1 METABOLIC SYNDROME IN PEOPLE WITH SEVERE MENTAL ILLNESS Introduction Marc De Hert, M.D. Ph.D., Professor Psychiatry, UPC KU Leuven, Campus Kortenberg, Leuvense Steenweg 517, B-3070 Kortenberg, Belgium People with severe mental illnesses (SMI), such as schizophrenia or bipolar disorder, have a reduced life expectancy compared to the general population [1-7]. They have a 2-3 fold increased risk of dying and that the mortality gap associated with mental illness compared to the general population has widened in recent decades [7]. People with severe mental illness have nearly twice the normal risk of dying from cardiovascular disease (CVD) [1-7]. In the psychiatric community this has lead in recent years to an increased interest in physical illnesses in people with SMI, specifically with regard to CVD risk. Cardio-metabolic Risk in SMI People with SMI are more likely to be overweight, to smoke, and to have hyperglycemia/diabetes, hypertension, and dyslipidemia [8-15] (Table1). In part these cardiometabolic risk factors are attributable to an unhealthy lifestyle, including poor diet and sedentary behavior. But over recent years it has become apparent that antipsychotic agents (AP) can have a negative impact on some of the modifiable risk factors [8-15] (Table 2). Part of this negative impact can be explained by the liability of some antipsychotics to induce significant weight gain [16-18]. A recent study indicates that these metabolic changes are dose independent [19]. Metabolic syndrome (MetS) brings together a series of abnormal clinical and metabolic findings which are predictive of CV risk, though there is continuing debate around the use of the term [20-29]. The concept has found its way into the psychiatric literature helping psychiatric clinicians to focus more on CVD risk in patients treated with AP [30-37]. To date 40 different studies have yielded consistent results showing elevated rates of MetS in both patients with schizophrenia and bipolar disorder [32]. In the largest study, the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study, approximately one third of patients in CATIE met National Cholesterol Education Program (NCEP) criteria for metabolic syndrome at baseline [33-34]. A troubling finding was that 88% of patients with dyslipidemia were not receiving treatment, as were 62% of the hypertensive patients and 38% of those with diabetes [35]. Some antipsychotic agents were associated with more significant adverse effects on weight, lipids, and glucose metabolism than others [34]. A large Belgian study found similar rates of MetS, which were 2 to 3 fold higher than in an age-adjusted population sample [32,36]. The prevalence of diabetes per age-band was 4-5 times higher in schizophrenia patients than in the general population. In a recent study of metabolic syndrome in patients diagnosed with schizophrenia from compared to , those started on second generation antipsychotics (SGA) had over twice the rate of new incident cases of metabolic syndrome after three years, compared to those treated with first generation antipsychotic agents (27.8% versus 9.8%) [37]. In patients
2 without metabolic syndrome at baseline, the risk of developing this combination of metabolic abnormalities was significantly greater in patients started on SGA (odds ratio 3.6) [37]. The majority of evidence is in patients with schizophrenia who are taking antipsychotic medication. There is, however, emerging evidence that there is an increase of modifiable CV risk factors, such as diabetes, in patients with bipolar disorder and in those with a history of depression and/or taking drugs to treat depression [38-40]. We recently reported on elevated rates of MetS in bipolar patients [41]. In another study we found that psychiatric diagnosis independent of medication and other confounding factors independently influenced the risk for MetS, with people with schizoaffective disorder having higher risk than people with schizophrenia or bipolar disorder [42]. Until recently there was no data on the safety and efficacy of statins in patients also exposed to antipsychotics. In patients with schizophrenia statins were an effective and safe treatment for severe dyslipidemia but they did not succeed in reversing MetS [43-44]. Growing evidence suggests that children and adolescents who take antipsychotic medication are at higher risk of weight gain and metabolic effects than adults who use the same drugs [45-48]. Guidelines for Screening and Monitoring Prevention should be of key importance. Clinicians should take into account both the present CVD risk as well as the metabolic risk profile of the antipsychotic chosen. Diet and lifestyle interventions should be started early after treatment initiation. Despite the risks many patients with SMI have limited access to general healthcare with less opportunity for cardiovascular risk screening and prevention than would be expected in a non-psychiatric population [3,49]. There is a lack of consensus over who should take responsibility for the general healthcare needs of mental health patients which has resulted in a continuing failure to provide appropriate services. General health care needs in this population were commonly neglected and psychiatrists mainly focus on efficacy of treatment of psychotic symptoms [3,5,14-15]. Over recent years both national and international groups have developed screening and monitoring guidelines [9,50-56] but these have not made their way to routine clinical care for patients [57-58]. If a patient develops metabolic abnormalities (e.g. weight gain, increased blood pressure, glucose, or lipid levels) following initiation of antipsychotic therapy, consideration should be given to switching the patients to an SGA which has not been associated with significant weight gain or diabetes. Initiation of appropriate blood pressure, glucose, or lipid lowering therapy should also be considered, in consultation with the patient s GP when that is possible, or with a specialist physician when this is considered appropriate [3,54]. A European current update of screening and monitoring guidance is being written by the EPA in collaboration with ESAD and ESC [59,60]. Conclusions Mets and other CVD risk factors are highly prevalent in people with SMI. The psychiatrist needs to be aware of the potential metabolic side-effects of antipsychotic medication and to include them in the risk/benefit assessment when choosing a specific antipsychotic. He should also be
3 responsible for the implementation of the necessary screening assessments and referral for treatment of any physical illness. Multidisciplinary assessment of psychiatric and medical conditions is needed. The somatic treatments offered to people with severe and enduring mental illness should be at par with general health care in the non-psychiatrically ill population [3,49]. References 1. Angst F, Stassen HH, Clayton PJ, Angst J Mortality of patients with mood disorders: follow-up over years. J Affect Disord 68(2-3): Brown S Excess mortality of schizophrenia. A meta-analysis. Br J Psychiatry 171: Fleischhacker WW, Cetkovich-Bakmas M, De Hert M, et al Cormorbid somatic illnesses in patients with severe mental disorders: clinical, policy and research challenges. J Clin Psych 69: Hennekens CH, Hennekens AR, Hollar D, Casey DE Schizophrenia and increased risks of cardiovascular disease. Am Heart J 150: Leucht S, Burkard T, Henderson J, Maj M, Sartorius N Physical illness and schizophrenia: a review of the literature. Acta Psychiatr Scand 116: Ösby U, Correia N, Brandt L, et al Mortality and causes of death in schizophrenia in Stockholm county, Sweden. Schizophr Res 45(1-2): Saha S, Chant D, McGrath J A systematic review of mortality in schizophrenia. Arch Gen Psychiatry 64: Correll CU Balancing efficacy and safety in the treatment with antipsychotics. CNS Spectrums 12(Suppl.17): Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes Diabetes Care 27: De Hert M, van Winkel R, van Eyck D, et al Prevalence of the metabolic syndrome in patients with schizophrenia treated with antipsychotic medication. Schizophr Res 83: Newcomer JW Second-generation (atypical) antipsychotics and metabolic effects a comprehensive literature review. CNS Drugs 19(Suppl.1): Scheen AJ, De Hert MA Abnormal glucose metabolism in patients treated with antipsychotics. Diabetes Metab 33: Tschoner A, Engl J, Laimer M, et al Metabolic side effects of antipsychotic medication. Int J Clin Pract 61(8): Meyer JM, Nasrallah HA Medical illness and schizophrenia. Washington, DC: American Psychiatric Publishing. 15. Voruganti LP, Punthakee Z, Van Lieshout RJ, et al Dysglycemia in a community sample of people treated for schizophrenia: the Diabetes in Schizophrenia in Central-South Ontario (DiSCO) study. Schizophr Res 96: Allison DB, Mentore JL, Heo M, et al Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 156(11): Citrome L Risk-benefit analysis of available treatments for schizophrenia. Psychiatric Times Suppl 1: Kinon BJ, Kaiser CJ, Ahmed S, et al Association between early and rapid weight gain and change in weight over one year of olanzapine therapy in patients with schizophrenia and related disorders. J Clin Psychopharmacol 25(3): Simon V, van Winkel R, De Hert M Are weight gain and metabolic side-effects of atypical antipsychotics dose-dependent? A literature review. J Clin Psychiatry In press. 20. Alberti KGMM, Zimmet P, Shaw J Metabolic syndrome a new world-wide definition. A consensus statement from the International Diabetes Federation. Diabetic Med 23:
4 21. Byrne CD, Wild SH The global burden of the metabolic syndrome and its consequences for diabetes and cardiovascular disease. In: Byrne CD, Wild SH, eds. The metabolic syndrome. West Sussex, MD: John Wiley & Sons, Ford ES, Giles WH, Mokdad AH Increasing prevalence of the metabolic syndrome among US adults. Diabetes Care 27(10): Grundy SM, Cleeman JI, Daniels SR, et al Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 112: Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285: Grundy SM, Brewer HB, Cleeman JI, Smith SC, Lenfant D, for the Conference Participants Definition of metabolic syndrome: report of the National, Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 109: Grundy SM The changing face of cardiovascular risk. JACC 46: Isomaa B, Almgren P, Tuomi T, et al Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 24(4): Kahn R, Buse J, Ferranninni E, Stern M The metabolic syndrome: time for a critical appraisal. Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 28: Lorenzo C, Hunt KJ, Williams K, Haffner SM The National Cholesterol Education Program Adult Treatment Panel III, International Diabetes Federation, and World Health Organization definitions of the metabolic syndrome as predictors of incident cardiovascular disease and diabetes. Diabetes Care 30: Arango C, Bobes J, Aranda P, Carmena R, Garcia-Garcia M, Rejas J; on behalf of the CLAMORS Study Collaborative Group A comparison of schizophrenia outpatients treated with antipsychotics with and without metabolic syndrome: findings from the CLAMORS study. Schizophr Res Jul 5. [Epub ahead of print]. 31. Bobes J, Arango C, Aranda P, Carmena R, Garcia-Garcia M, Rejas J; CLAMORS Study Collaborative Group Cardiovascular and metabolic risk in outpatients with schizophrenia treated with antipsychotics: results of the CLAMORS Study. Schizophr Res 90(1-3): De Hert M, van Winkel R The metabolic syndrome in patients treated with antipsychotic medication. World Psychiatry Submitted. 33. Goff DC, Sullivan LM, McEvoy JP, et al A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls. Schizophr Res 80(1): Meyer JM, Davis VG, Goff DC, et al Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: prospective data from phase 1 Schizophr Res 101(1-3): Nasrallah HA, Meyer JM, Goff DC, et al Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline. Schizophr Res 86(1-3): De Hert M, van Winkel R, Van Eyck D, et al Prevalence of diabetes, metabolic syndrome and metabolic abnormalities in schizophrenia over the course of the illness: a cross-sectional study. Clin Pract Epidemiol Ment Health 2: De Hert M, Schreurs V, Sweers K, et al Typical and atypical antipsychotics differentially affect long-term incidence rates of the metabolic syndrome in first-episode patients with schizophrenia: a retrospective chart review. Schizophr Res 101(1-3):
5 38. Brown LC, Majumdar SR, Newman SC, Johnson JA History of depression increases risk of type 2 diabetes in younger adults. Diabetes Care 28: Rubin RR, Marrero DG, Peyrot M, et al Elevated depression symptoms, antidepressant medicine use, and risk of developing diabetes during the diabetes prevention program. Diabetes Care 31: Hill Golden S, Lazo M, Carnethon M, et al Examining a bidirectional association between depressive symptoms and diabetes. JAMA 299(23): van Winkel R, De Hert M, Van Eyck D, et al Prevalence of diabetes and the metabolic syndrome in a sample of patients with bipolar disorder. Bipolar Disord 10: van Winkel W, van Os J, Celic I, et al Psychiatric diagnosis as an independent risk factor for metabolic disturbances. Results from a comprehensive, naturalistic screening program. J Clin Psychiatry 69: De Hert M, Kalnicka D, van Winkel R, et al Treatment with rosuvastatin for severe dyslipidemia in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 67(12): Hanssens L, De Hert M, Kalnicka D, et al Pharmacological treatment of severe dyslipidaemia in patients with schizophrenia. Int Clin Psychopharmacol 22: Correll CU Assessing and maximizing the safety and tolerability of antipsychotics used in the treatment of children and adolescents. J Clin Psychiatry 69(Suppl.4): Daniels SR, Greer FR and the Committee on Nutrition Lipid screening and cardiovascular health in childhood. Pediatrics 122: Kumra S, Oberstar JV, Sikich L, et al Efficacy and tolerability of second-generation antipsychotics in children and adolescents with schizophrenia. Schizophr Bull 34: Zimmet P, Alberti G, Kaufman K, et al The metabolic syndrome in children and adolescents. Lancet 369: Druss BG Improving medical care for persons with serious mental illness: challenges and solutions. J Clin Psych 68(Suppl.4): Barnett AH, Mackin P, Chaudhry I, et al Minimising metabolic and cardiovascular risk in schizophrenia: diabetes, obesity and dyslipidaemia. J Psychopharmacol 21: Citrome L, Yeomans D Do guidelines for severe mental illness promote physical health and well-being? J Psychopharmacol 19: Cohn TA, Sernyak MJ Metabolic monitoring for patients treated with antipsychotic medications. Can J Psychiatry 51: De Hert M, van Eyck D, Hanssens L, et al Oral glucose tolerance tests in treated patients with schizophrenia. Data to support an adaptation of the proposed guidelines for monitoring of patients on second generation antipsychotics? Eur Psychiatry 21: De Hert M, van Eyck D, De Nayer A Metabolic abnormalities associated with second generation antipsychotics: fact or fiction? Development of guidelines for screening and monitoring. Int Clin Psychopharmacol 21(Suppl.2): S11-S Marder SR, Essock SM, Miller AL, et al Physical health monitoring of patients with schizophrenia. Am J Psychiatry 161: van Winkel R, De Hert M, Van Eyck D, et al Screening for diabetes and other metabolic abnormalities in patients with schizophrenia and schizoaffective disorder: evaluation of incidence and screening methods. J Clin Psychiatry 67(10): Buckley PF, Miller D, Singer B, Arena J, Stirewalt EM Clinicians' recognition of the metabolic adverse effects of antipsychotic medications. Schizophr Res 79: Newcomer JW, Nasrallah HA, Loebel AD The Atypical Antipsychotic Therapy and Metabolic Issues National Survey: practice patterns and knowledge of psychiatrists. J Clin Psychopharmacol 24(5 Suppl.1): S1-S Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice European guidelines on
6 cardiovascular disease prevention in clinical practice: executive summary. Eur J Cardiovasc Prev Rehabil 14(Suppl.2): E1-E The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD) Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. Eur Heart J 28:
7 Table 1: Estimated Prevalence and RR of Modifiable Cardiovascular Disease Risk Factors in Schizophrenia and Bipolar Disorder Compared to the General Population [8] Estimated Prevalence and Relative Risk Modifiable Risk Factors Schizophrenia Bipolar Disorder Obesity 45%-55% RR: %-49% RR: 1-2 Smoking 50%-80% RR: %-68% RR: 2-3 Diabetes 10%-15% RR: 2 8%-17% RR: Hypertension 19%-58% RR: %-61% RR: 2-3 Dyslipidemia 25%-69% RR: 5 23%-38% RR: 3 Metabolic Syndrome 37%-63% RR: %-49% RR: RR=relative risk.
8 Table 2: Second generation antipsychotic agents and metabolic abnormalities [9,13,54] Antipsychotic Weight gain Risk for diabetes Worsening lipid profile Clozapine Olanzapine Risperidone ++?? Quetiapine ++?? Aripiprazole + No report No report Ziprasidone + No report No report Amisulpride + No report No report * Cases of diabetes have now been reported with all the SGAs, but the difference in relative risk remains the same; no report: at moment of publication no cases reported, since then cases of diabetes have been reported with all SGA
Antipsychotic Medications and the Risk of Diabetes and Cardiovascular Disease
Antipsychotic Medications and the Risk of Diabetes and Cardiovascular Disease Professional Tool #1: Screening and Monitoring in a High-Risk Population: Questions and Answers Overview of Cardiometabolic
More informationBarriers to Healthcare Services for People with Mental Disorders. Cardiovascular disorders and diabetes in people with severe mental illness
Barriers to Healthcare Services for People with Mental Disorders Cardiovascular disorders and diabetes in people with severe mental illness Dr. med. J. Cordes LVR- Klinikum Düsseldorf Kliniken der Heinrich-Heine-Universität
More informationImproving cardiometabolic health in Major Mental Illness
Improving cardiometabolic health in Major Mental Illness Dr. Adrian Heald Consultant in Endocrinology and Diabetes Leighton Hospital, Crewe and Macclesfield Research Fellow, Manchester University Metabolic
More informationPrevalence of diabetes and the metabolic syndrome in a sample of patients with bipolar disorder *
Prevalence of diabetes and the metabolic syndrome in a sample of patients with bipolar disorder * Ruud van Winkel a, Marc De Hert a, Dominique Van Eyck a, Linda Hanssens b, Martien Wampers a, Andre Scheen
More informationDiabetes and cardiovascular risk in severe mental illness: a missed opportunity and challenge for the future
Diabetes and cardiovascular risk in severe mental illness: a missed opportunity and challenge for the future RIG Holt*, RC Peveler Introduction Schizophrenia and bipolar disorder are major psychiatric
More informationHEDIS CY2012 New Measures
HEDIS CY2012 New Measures TECHNICAL CONSIDERATIONS FOR NEW MEASURES The NCQA Committee on Performance Measurement (CPM) approved five new measures for HEDIS 2013 (CY2012). These measures provide feasible
More informationCardiovascular disease and diabetes in people with severe mental illness: causes, consequences and pragmatic management
Cardiovascular disease and diabetes in people with severe mental illness: causes, consequences and pragmatic management Richard IG Holt Human Development and Health Academic Unit, Faculty of Medicine,
More informationMental Health Disorders in Alberta
Chapter 9 and Mental Health Disorders in Alberta Lauren C. Bresee Larry W. Svenson Scott B. Patten ALBERTA DIABETES ATLAS 9 175 176 ALBERTA DIABETES ATLAS 9 DIABETES AND MENTAL HEALTH DISORDERS IN ALBERTA
More informationEuropean Psychiatry 24 (2009) 412 424. Review
European Psychiatry 24 (2009) 412 424 Review Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the
More informationRobert Okwemba, BSPHS, Pharm.D. 2015 Philadelphia College of Pharmacy
Robert Okwemba, BSPHS, Pharm.D. 2015 Philadelphia College of Pharmacy Judith Long, MD,RWJCS Perelman School of Medicine Philadelphia Veteran Affairs Medical Center Background Objective Overview Methods
More informationDet metaboliske Syndrom Hvad er risikoen hos patienter? Hvad gør NIP skizofreni på området?
Det metaboliske Syndrom Hvad er risikoen hos patienter? Hvad gør NIP skizofreni på området? Henrik Lublin Centerchef, dr.med. Psykiatrisk Center Glostrup Increased Mortality Rates for Medical Disorders
More informationAtypical antipsychotics and the metabolic syndrome. Thomas R. Dekoj, MS3 UIC College of Medicine
Atypical antipsychotics and the metabolic syndrome Thomas R. Dekoj, MS3 UIC College of Medicine Antipsychotic uses Schizophrenia and related d/o ~1% Bipolar ~2% used widely in schizophrenia spectrum d/o,
More informationMETABOLIC SYNDROME IN A CORRECTIONS POPULATION TREATED WITH ANTIPSYCHOTICS
METABOLIC SYNDROME IN A CORRECTIONS POPULATION TREATED WITH ANTIPSYCHOTICS Andrew M. Cislo, PhD Megan J. Ehret, PharmD, MS, BCPP Robert L. Trestman, MD, PhD Kirsten Shea, MBA www.uchc.edu Background Metabolic
More informationSerious Mental Illness: Symptoms, Treatment and Causes of Relapse
Serious Mental Illness: Symptoms, Treatment and Causes of Relapse Bipolar Disorder, Schizophrenia and Schizoaffective Disorder Symptoms and Prevalence of Bipolar Disorder Bipolar disorder, formerly known
More informationANNALS OF CLINICAL PSYCHIATRY
ANNALS OF CLINICAL PSYCHIATRY ANNALS OF CLINICAL PSYCHIATRY 2013;25(1):17-26 RESEARCH ARTICLE A simulation model to estimate 10-year risk of coronary heart disease events in patients with schizophrenia
More informationTrends in Prescribing of Antipsychotic Drugs in General Practice in England (Chart 1) 2.0. Other second generation antipsychotics (SGA)
Antipsychotic drugs Antipsychotics can be broadly classified into first generation antipsychotics (FGAs, formerly known as typical antipsychotics) and second generation antipsychotics (SGAs, formerly known
More informationThe Maryland Public Behavioral Health System
The Maryland Public Behavioral Health System Arleen Rogan, Ph.D. Division Director, Integrated Health Services Family Services, Inc. Arleen.rogan@fs-inc.org Behavioral Health includes: Mental health conditions
More informationImproving the Recognition and Treatment of Bipolar Depression
Handout for the Neuroscience Education Institute (NEI) online activity: Improving the Recognition and Treatment of Bipolar Depression Learning Objectives Apply evidence-based tools that aid in differentiating
More informationNorth of Tyne Area Prescribing Committee
North of Tyne Area Prescribing Committee ANTIPSYCHOTICS IN PSYCHOSIS, BIPOLAR DISORDER AND AUGMENTATION THERAPY IN TREATMENT RESISTANT DEPRESSION Information for Primary Care Updated November 2013 This
More informationHow To Know If You Die From A Psychotic Disorder
Comorbidity and mortality in patients with psychotic disorders Ingrid Dieset MD, PhD NORMENT-KG Jebsen senter for psykoseforskning (TOP) Universitetet i Oslo Nydalen DPS WHO Mental and substance use disorders
More informationDiagnosis, classification and prevention of diabetes
Diagnosis, classification and prevention of diabetes Section 1 1 of 4 Curriculum Module II 1 Diagnosis, classification and presentation of diabetes Slide 2 of 48 Polyurea Definition of diabetes Slide 3
More informationPreferred Practice Guidelines Bipolar Disorder in Children and Adolescents
These Guidelines are based in part on the following: American Academy of Child and Adolescent Psychiatry s Practice Parameter for the Assessment and Treatment of Children and Adolescents With Bipolar Disorder,
More informationPharmacological Management of Prodromal and First Episode Schizophrenia
Pharmacological Management of Prodromal and First Episode Schizophrenia The optimal time to treat schizophrenia is as early in the course and as close to the onset as possible. Often the onset of the illness
More informationDiabetes prevalence estimates in schizophrenia and risk factor assessment
Annals of Clinical Psychiatry Annals of Clinical Psychiatry 2011;23(2):117-124 Research Article Diabetes prevalence estimates in schizophrenia and risk factor assessment Tami Argo, PharmD, MS, BCPP Iowa
More informationConjoint Professor Brian Draper
Chronic Serious Mental Illness and Dementia Optimising Quality Care Psychiatry Conjoint Professor Brian Draper Academic Dept. for Old Age Psychiatry, Prince of Wales Hospital, Randwick Cognitive Course
More informationMetabolic Syndrome Overview: Easy Living, Bitter Harvest. Sabrina Gill MD MPH FRCPC Caroline Stigant MD FRCPC BC Nephrology Days, October 2007
Metabolic Syndrome Overview: Easy Living, Bitter Harvest Sabrina Gill MD MPH FRCPC Caroline Stigant MD FRCPC BC Nephrology Days, October 2007 Evolution of Metabolic Syndrome 1923: Kylin describes clustering
More informationDEPRESSION Depression Assessment PHQ-9 Screening tool Depression treatment Treatment flow chart Medications Patient Resource
E-Resource March, 2015 DEPRESSION Depression Assessment PHQ-9 Screening tool Depression treatment Treatment flow chart Medications Patient Resource Depression affects approximately 20% of the general population
More informationPopulation Health Management Program
Population Health Management Program Program (formerly Disease Management) is dedicated to improving our members health and quality of life. Our Population Health Management Programs aim to improve care
More informationThe connection between diabetes and. Managing diabetes in people with severe mental illness. John Pendlebury, Richard IG Holt
Managing diabetes in people with severe mental illness Article points 1. Diabetes is two to three times more common in people with severe mental illness (SMI) than in the general population. 2. The reasons
More informationAntipsychotic Medications and the Risk of Diabetes and Cardiovascular Disease
Antipsychotic Medications and the Risk of Diabetes and Cardiovascular Disease Patient Tool #1 Understanding Diabetes and Psychiatric Illness: A Guide for Individuals, Families, and Caregivers Type 2 Diabetes,
More informationATYPICALS ANTIPSYCHOTIC MEDICATIONS
The atypical antipsychotics are a class of drugs that are used to treat a number of behavioral health disorders, including schizophrenia, other psychotic disorders, mood disorders, and behavioral agitation
More informationLiving with Schizophrenia
World Mental Health Day 2014 Living with Schizophrenia 1 section V Time To Act LIVING A HEALTHY LIFE WITH SCHIZOPHRENIA: PAVING THE ROAD TO RECOVERY M.T. Yasamy, A. Cross, E. McDaniell, S. Saxena Background
More informationEmergency Room Treatment of Psychosis
OVERVIEW The term Lewy body dementias (LBD) represents two clinical entities dementia with Lewy bodies (DLB) and Parkinson s disease dementia (PDD). While the temporal sequence of symptoms is different
More informationSummary of the risk management plan (RMP) for Aripiprazole Pharmathen (aripiprazole)
EMA/303592/2015 Summary of the risk management plan (RMP) for Aripiprazole Pharmathen (aripiprazole) This is a summary of the risk management plan (RMP) for Aripiprazole Pharmathen, which details the measures
More informationAntipsychotic drugs are the cornerstone of treatment
Article Effectiveness of Olanzapine, Quetiapine, Risperidone, and Ziprasidone in Patients With Chronic Schizophrenia Following Discontinuation of a Previous Atypical Antipsychotic T. Scott Stroup, M.D.,
More information2. The prescribing clinician will register with the designated manufacturer.
Clozapine Management Program Description Magellan of Arizona Pharmacy Program Background: Magellan Health Services of Arizona recognizes the importance of a clozapine program. Clozapine received increased
More informationType 1 Diabetes ( Juvenile Diabetes)
Type 1 Diabetes W ( Juvenile Diabetes) hat is Type 1 Diabetes? Type 1 diabetes, also known as juvenile-onset diabetes, is one of the three main forms of diabetes affecting millions of people worldwide.
More informationJill Malcolm, Karen Moir
Evaluation of Fife- DICE: Type 2 diabetes insulin conversion Article points 1. Fife-DICE is an insulin conversion group education programme. 2. People with greater than 7.5% on maximum oral therapy are
More information1AC. All definitions will be contextually defined and the affirmative reserves the right to clarify upon further scrutiny.
Marilyn Elias, USA Today, 05/02/2006 New antipsychotic drugs carry risks for children Nancy Thomas remembers the bad old days when she had to wear long-sleeve clothes to church to cover bite marks all
More informationCardiac Rehabilitation: An Under-utilized Resource Making Patients Live Longer, Feel Better
Cardiac Rehabilitation: An Under-utilized Resource Making Patients Live Longer, Feel Better Marian Taylor, M.D. Medical University of South Carolina Director, Cardiac Rehabilitation I have no disclosures.
More informationHow To Prevent Type 2 Diabetes
Introduction The Primary Prevention of Type 2 Diabetes AADE Practice Synopsis Issued December 1, 2014 The prevalence of type 2 diabetes is reaching epidemic proportions with more than 9.3% of adults in
More informationMental Health Referral Practices and Diabetic Management at Community Medical Alliance Clinic (Bell Site) Northeast Community Clinic (NECC)
Mental Health Referral Practices and Diabetic Management at Community Medical Alliance Clinic (Bell Site) Northeast Community Clinic (NECC) MaryAnn Garcia, SUNY Downstate Medical College NMF PCLP Scholar
More informationMajor Depressive Disorder:
Major Depressive Disorder: An Actuarial Commercial Claim Data Analysis July 2013 Prepared by: Milliman, Inc. NY Kate Fitch RN, MEd Kosuke Iwasaki FIAJ, MAAA, MBA This report was commissioned by Takeda
More information6.4 Diabetes. 6 Priority diseases and reasons for inclusion. Background. Developments since 2004. See Background Paper 6.4 (BP6_4DM.
6 Priority diseases and reasons for inclusion 6.4 Diabetes See Background Paper 6.4 (BP6_4DM.pdf) Background Diabetes and diabetes-related illnesses place an enormous burden on the health care systems
More informationBipolar Disorder and Substance Abuse Joseph Goldberg, MD
Diabetes and Depression in Older Adults: A Telehealth Intervention Julie E. Malphurs, PhD Asst. Professor of Psychiatry and Behavioral Science Miller School of Medicine, University of Miami Research Coordinator,
More informationBig data size isn t enough! Irene Petersen, PhD Primary Care & Population Health
Big data size isn t enough! Irene Petersen, PhD Primary Care & Population Health Introduction Reader (Statistics and Epidemiology) Research team epidemiologists/statisticians/phd students Primary care
More informationStatins and Risk for Diabetes Mellitus. Background
Statins and Risk for Diabetes Mellitus Kevin C. Maki, PhD, FNLA Midwest Center for Metabolic & Cardiovascular Research and DePaul University, Chicago, IL 1 Background In 2012 the US Food and Drug Administration
More informationPAYMENT INNOVATIONS SUPPORTING BEHAVIORAL HEALTHCARE DELIVERY IMPROVEMENT. NGA July 2015
PAYMENT INNOVATIONS SUPPORTING BEHAVIORAL HEALTHCARE DELIVERY IMPROVEMENT NGA July 2015 My Background Medicaid Director Previously DMH Medical Director 20 years Practicing Psychiatrist CMHCs 10 years FQHC
More informationTreatment of Bipolar Disorders with Second Generation Antipsychotic Medications
Neuroendocrinology Letters ISSN 0172-780X Vol. 26, Supplement 1, August 2005 Treatment of Bipolar Disorders with Second Generation Antipsychotic Medications Marek Jarema Ljubomir Hotujac E. Timucin Oral
More informationClinical Research on Lifestyle Interventions to Treat Obesity and Asthma in Primary Care Jun Ma, M.D., Ph.D.
Clinical Research on Lifestyle Interventions to Treat Obesity and Asthma in Primary Care Jun Ma, M.D., Ph.D. Associate Investigator Palo Alto Medical Foundation Research Institute Consulting Assistant
More informationESC/EASD Pocket Guidelines Diabetes, pre-diabetes and cardiovascular disease
Diabetes, prediabetes and cardiovascular disease Classes of recommendations Levels of evidence Recommended treatment targets for patients with diabetes and CAD Definition, classification and screening
More informationHow To Safely Use Aripiprazole
VI.2 Elements for a Public Summary VI.2.1 Overview of disease epidemiology Bipolar I Disorder Reported prevalence rates for bipolar I disorder differ due to local variations in psychiatric practice, variations
More informationCardiac Rehabilitation The Best Medicine for Your CAD Patients. James A. Stone
James A. Stone BPHE, BA, MSc, MD, PhD, FRCPC, FAACVPR, FACC Clinical Professor of Medicine, University of Calgary Total Cardiology, Calgary Acknowledgements and Disclosures Acknowledgements Jacques Genest
More informationPrevention of and the Screening for Diabetes Part I Insulin Resistance By James L. Holly, MD Your Life Your Health The Examiner January 19, 2012
Prevention of and the Screening for Diabetes Part I Insulin Resistance By James L. Holly, MD Your Life Your Health The Examiner January 19, 2012 In 2002, SETMA began a relationship with Joslin Diabetes
More informationPsychotic Disorder. Psychosis. Psychoses may be caused by: Examples of Hallucinations and Delusions 12/12/2012
Psychosis Psychotic Disorder Dr Lim Boon Leng Psychiatrist and Medical Director Dr BL Lim Centre For Psychological Wellness Tel: 64796456 Email: info@psywellness.com.sg Web: www.psywellness.com.sg A condition
More informationDepression in patients with coronary heart disease (CHD): screening, referral and treatment. 2014 Na)onal Heart Founda)on of Australia
Depression in patients with coronary heart disease (CHD): screening, referral and treatment Screening, referral and treatment for depression in patients with CHD A consensus statement from the National
More informationPCHC FACTS ABOUT HEALTH CONDITIONS AND MOOD DIFFICULTIES
PCHC FACTS ABOUT HEALTH CONDITIONS AND MOOD DIFFICULTIES Why should mood difficulties in individuals with a health condition be addressed? Many people with health conditions also experience mood difficulties
More informationTHE STUDY OF NEWLY DISCOVERED CASES OF DIABETES MELLITUS IN BIHOR COUNTY
Analele UniversităŃii din Oradea Fascicula:Ecotoxicologie, Zootehnie şi Tehnologii de Industrie Alimentară, 2012 THE STUDY OF NEWLY DISCOVERED CASES OF DIABETES MELLITUS IN BIHOR COUNTY *University of
More informationPsoriasis Co-morbidities: Changing Clinical Practice. Theresa Schroeder Devere, MD Assistant Professor, OHSU Dermatology. Psoriatic Arthritis
Psoriasis Co-morbidities: Changing Clinical Practice Theresa Schroeder Devere, MD Assistant Professor, OHSU Dermatology Psoriatic Arthritis Psoriatic Arthritis! 11-31% of patients with psoriasis have psoriatic
More informationThese guidelines are intended to support General Practitioners in the care of their patients with dementia both in the community and in care homes.
This is a new guideline. These guidelines are intended to support General Practitioners in the care of their patients with dementia both in the community and in care homes. It incorporates NICE clinical
More informationHow To Ensure That Children With Angegea Are Treated Properly
Department of Health and Human Services OFFICE OF INSPECTOR GENERAL SECOND-GENERATION ANTIPSYCHOTIC DRUG USE AMONG MEDICAID-ENROLLED CHILDREN: QUALITY-OF-CARE CONCERNS Daniel R. Levinson Inspector General
More informationListen to your heart: Good Cardiovascular Health for Life
Listen to your heart: Good Cardiovascular Health for Life Luis R. Castellanos MD, MPH Assistant Clinical Professor of Medicine University of California San Diego School of Medicine Sulpizio Family Cardiovascular
More informationTABLE OF CONTENTS. The Cost of Diabesity... 3. Employer Solutions... 4 Provide a Worksite Weight Loss Program Tailored for Diabetes...
TH E TABLE OF CONTENTS The Cost of Diabesity... 3 Employer Solutions... 4 Provide a Worksite Weight Loss Program Tailored for Diabetes... 4 Provide Healthy Food Options at the Workplace... 4 Make it Easy
More informationTreating Patients with PRE-DIABETES David Doriguzzi, PA-C First Valley Medical Group. Learning Objectives. Background. CAPA 2015 Annual Conference
Treating Patients with PRE-DIABETES David Doriguzzi, PA-C First Valley Medical Group Learning Objectives To accurately make the diagnosis of pre-diabetes/metabolic syndrome To understand the prevalence
More informationIntegrated Health Care Models and Practices
Integrated Health Care Models and Practices The Greater Houston Behav io r al Health Affordable Care Act Initiative S e c o n d C o m m u n i t y E d u c a t i o n E v e n t I n t e g r a t e d H e a l
More informationPsychotropic Drug Induced Metabolic Disorders
DELHI PSYCHIATRY JOURNAL Vol. 10 No.1 APRIL 2007 Review Article Psychotropic Drug Induced Metabolic Disorders J.K. Trivedi, Kumar Gaurav Department of Psychiatry, K.G. Medical University, Lucknow-226003
More informationI. The Positive Symptoms...Page 2. The Negative Symptoms...Page 2. Primary Psychiatric Conditions...Page 2
SUTTER PHYSICIANS ALLIANCE (SPA) 2800 L Street, 7 th Floor Sacramento, CA 95816 SPA PCP Treatment & Referral Guideline Assessment & Treatment of Psychosis Developed March 1, 2003 Revised September 21,
More informationUniversity of Warwick institutional repository: http://go.warwick.ac.uk/wrap
University of Warwick institutional repository: http://go.warwick.ac.uk/wrap This paper is made available online in accordance with publisher policies. Please scroll down to view the document itself. Please
More informationSecond- and Third-Line Approaches for Type 2 Diabetes Workgroup: Topic Brief
Second- and Third-Line Approaches for Type 2 Diabetes Workgroup: Topic Brief March 7, 2016 Session Objective: The objective of this workshop is to assess the value of undertaking comparative effectiveness
More informationTake a moment Confer with your neighbour And try to solve the following word picture puzzle slides.
Take a moment Confer with your neighbour And try to solve the following word picture puzzle slides. Example: = Head Over Heels Take a moment Confer with your neighbour And try to solve the following word
More informationNutrition. Type 2 Diabetes: A Growing Challenge in the Healthcare Setting NAME OF STUDENT
1 Nutrition Type 2 Diabetes: A Growing Challenge in the Healthcare Setting NAME OF STUDENT 2 Type 2 Diabetes: A Growing Challenge in the Healthcare Setting Introduction and background of type 2 diabetes:
More informationBelow, this letter outlines [patient name] s medical history, prognosis, and treatment rationale.
[Date] [Name of Contact] [Title] [Name of Health Insurance Company] [Address] [City, State, Zip Code] Insured: [Patient Name] Policy Number: [Number] Group Number: [Number] Diagnosis: [Diagnosis and ICD-9-CM
More informationObesity and Socioeconomic Status in Children and Adolescents: United States, 2005 2008
Obesity and Socioeconomic Status in Children and Adolescents: United States, 2005 2008 Cynthia L. Ogden, Ph.D.; Molly M. Lamb, Ph.D.; Margaret D. Carroll, M.S.P.H.; and Katherine M. Flegal, Ph.D. Key findings
More informationFlorida Medicaid: Mental Health and Substance Abuse Services
Florida Medicaid: Mental Health and Substance Abuse Services Beth Kidder Assistant Deputy Secretary for Medicaid Operations Agency for Health Care Administration House Children, Families, and Seniors Subcommittee
More informationDelivery of Tobacco Dependence Treatment for Tobacco Users with Mental Illness and Substance Use Disorders (MISUD)
Delivery of Tobacco Dependence Treatment for Tobacco Users with Mental Illness and Substance Use Disorders (MISUD) Learning Objectives Upon completion of this module, you should be able to: Describe how
More informationPSYCHOPHARMACOLOGY AND WORKING WITH PSYCHIATRY PROVIDERS. Juanaelena Garcia, MD Psychiatry Director Institute for Family Health
PSYCHOPHARMACOLOGY AND WORKING WITH PSYCHIATRY PROVIDERS Juanaelena Garcia, MD Psychiatry Director Institute for Family Health Learning Objectives Learn basics about the various types of medications that
More informationTYPE 2 DIABETES MELLITUS: NEW HOPE FOR PREVENTION. Robert Dobbins, M.D. Ph.D.
TYPE 2 DIABETES MELLITUS: NEW HOPE FOR PREVENTION Robert Dobbins, M.D. Ph.D. Learning Objectives Recognize current trends in the prevalence of type 2 diabetes. Learn differences between type 1 and type
More information4/4/2013. Mike Rizo, Pharm D, MBA, ABAAHP THE PHARMACIST OF THE FUTURE? METABOLIC SYNDROME AN INTEGRATIVE APPROACH
METABOLIC SYNDROME AN INTEGRATIVE APPROACH AN OPPORTUNITY FOR PHARMACISTS TO MAKE A DIFFERENCE Mike Rizo, Pharm D, MBA, ABAAHP THE EVOLUTION OF THE PHARMACIST 1920s 1960s 2000s THE PHARMACIST OF THE FUTURE?
More informationDepression is a common biological brain disorder and occurs in 7-12% of all individuals over
Depression is a common biological brain disorder and occurs in 7-12% of all individuals over the age of 65. Specific groups have a much higher rate of depression including the seriously medically ill (20-40%),
More informationStudent Project PRACTICE-BASED RESEARCH. Key words: antidepressant, antipsychotic, assertive community treatment, medication management, monitoring
Development of a Medication Monitoring System for an Integrated Multidisciplinary Program of Assertive Community Treatment (IMPACT) Team Sarah C. Watkins*, PharmD Candidate 1 ; Bruce R. Winchester*, PharmD
More informationPost Traumatic Stress Disorder (PTSD) Karen Elmore MD Robert K. Schneider MD Revised 5-11-2001 by Robert K. Schneider MD
Post Traumatic Stress Disorder (PTSD) Karen Elmore MD Robert K. Schneider MD Revised 5-11-2001 by Robert K. Schneider MD Definition and Criteria PTSD is unlike any other anxiety disorder. It requires that
More informationA starting point for today 30/04/2015. Obesity does matter. Obesity is modifiable. Reducing weight has demonstrable health benefit
Obesity Intervention for Front-Line Healthcare Providers Welcome to our MBTelehealth sites! A special evaluation plan for the day Linking Learning to Practice for FPs: Earn 2 Mainpro-C and 2 bonus Mainpro
More informationBaskets of Care Diabetes Subcommittee
Baskets of Care Diabetes Subcommittee Disclaimer: This background information is not intended to be a comprehensive scientific discussion of the topic, but rather an attempt to provide a baseline level
More informationBenchmarking the Quality of Schizophrenia Pharmacotherapy: A Comparison of the Department of Veterans Affairs and the Private Sector
The Journal of Mental Health Policy and Economics J Ment Health Policy Econ 6, 113-121 (2003) Benchmarking the Quality of Schizophrenia Pharmacotherapy: A Comparison of the Department of Veterans Affairs
More informationClinical Summary of Pediatric Metabolic AERS Reports. Judith Cope, MD, MPH Office of Pediatric Therapeutics/FDA
Clinical Summary of Pediatric Metabolic AERS Reports Judith Cope, MD, MPH Office of Pediatric Therapeutics/FDA 1 Clinical Summary of Pediatric Metabolic AERS Reports: Atypical Antipsychotics n=100 reports;
More information4. Does your PCT provide structured education programmes for people with type 2 diabetes?
PCT Prescribing Report Drugs used in Type 2 Diabetes Discussion Points 1. Does your PCT have a strategy for prevention of type 2 diabetes? Does your PCT provide the sort of intensive multifactorial lifestyle
More informationUNDERSTANDING AND MANAGING METABOLIC SYNDROME IN PSYCHIATRY. Dr Sanil Rege MBBS, MRCPsych, FRANZCP Director of CTF Training Course
UNDERSTANDING AND MANAGING METABOLIC SYNDROME IN PSYCHIATRY Dr Sanil Rege MBBS, MRCPsych, FRANZCP Director of CTF Training Course Talks Director of the CTF Training course Overview of the metabolic syndrome
More informationMetabolic Monitoring for Patients Treated With Antipsychotic Medications
In Review Metabolic Monitoring for Patients Treated With Antipsychotic Medications Tony A Cohn, MB, ChB, MSc, FRCPC 1, Michael J Sernyak, MD 2 Objectives: Metabolic side effects of antipsychotic treatment
More informationBipolar Disorder. Mania is the word that describes the activated phase of bipolar disorder. The symptoms of mania may include:
Bipolar Disorder What is bipolar disorder? Bipolar disorder, or manic depression, is a medical illness that causes extreme shifts in mood, energy, and functioning. These changes may be subtle or dramatic
More informationCLINICIAN INTERVIEW COMPLEXITIES OF BIPOLAR DISORDER. Interview with Charles B. Nemeroff, MD, PhD
COMPLEXITIES OF BIPOLAR DISORDER Interview with Charles B. Nemeroff, MD, PhD Dr Nemeroff is the Reunette W. Harris Professor and Chairman of the Department of Psychiatry and Behavioral Sciences at Emory
More informationThis continuing education activity is co-sponsored by Indiana University School of Medicine and by CME Outfitters, LLC.
This continuing education activity is co-sponsored by Indiana University School of Medicine and by CME Outfitters, LLC. Indiana University School of Medicine and CME Outfitters, LLC, gratefully acknowledge
More informationPhysical and Mental Health Problems - The Consequences
Counting all the costs: the economic impacts of poor physical health in people with mental health problems: a briefing paper David McDaid and A-La Park Personal Social Services Research Unit, LSE Health
More informationlength of stay in hospital, sex, marital status, discharge status and diagnostic categories. Mean age and mean length of stay were compared for the
Clinical and Demographic Characteristics of Psychiatric Inpatients admitted via Emergency and Non-Emergency routes at a University Hospital in Pakistan E.U. Syed,R. Atiq ( Departments of Psychiatry, Aga
More informationBehavioral Health Quality Standards for Providers
Behavioral Health Quality Standards for Providers TABLE OF CONTENTS I. Behavioral Health Quality Standards Access Standards A. Access Standards B. After-Hours C. Continuity and Coordination of Care 1.
More informationThe prevalence of metabolic syndrome in patients with bipolar disorder
Journal of Affective Disorders 106 (2008) 197 201 www.elsevier.com/locate/jad Brief report The prevalence of metabolic syndrome in patients with bipolar disorder Maria P. Garcia-Portilla a,, Pilar A. Saiz
More informationCorrelates of Metabolic Abnormalities in Bipolar I Disorder at Initiation of Acute Phase Treatment
online ML Comm 0ORIGINAL ARTICLE0 Psychiatry Invest 2009;6:78-84 Print ISSN 1738-3684 / On-line ISSN 1976-3026 Correlates of Metabolic Abnormalities in Bipolar I Disorder at Initiation of Acute Phase Treatment
More informationHealth Education in Schools The Importance of Establishing Healthy Behaviors in our Nation s Youth
Health Education in Schools The Importance of Establishing Healthy Behaviors in our Nation s Youth A Statement from the American Cancer Society, the American Diabetes Association, and the American Heart
More informationDiabetes Complications
Managing Diabetes: It s s Not Easy But It s s Worth It Presenter Disclosures W. Lee Ball, Jr., OD, FAAO (1) The following personal financial relationships with commercial interests relevant to this presentation
More informationMental Health Care Services by Family Physicians (Position Paper)
Background Mental Health Care Services by Family Physicians (Position Paper) Mental health services are an essential element of the health care services continuum. Promotion of mental health and the diagnosis
More informationTHE RISK OF HEART ATTACK IN LONE MOTHERS by Asma Al Bulushi. I had been working as a nurse in the cardiology intensive care unit at Hamad Hospital
Al Bulushi, A. (2010). The risk of heart attack in lone mothers. UCQ Nursing Journal of Academic Writing, Winter 2010, 19 27. THE RISK OF HEART ATTACK IN LONE MOTHERS by Asma Al Bulushi I had been working
More information